Investigator-initiated study of two drugs after stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This study tests two drugs, selinexor and venetoclax, given after a stem cell transplant to keep high-risk leukemia or myelodysplastic syndrome from coming back. The goal is to see if this maintenance therapy is safe and effective for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a high-risk type of acute myeloid leukemia (AML) or a high-risk myelodysplastic syndrome (MDS).
- You are between 18 and 75 years old.
- You received a donor stem cell transplant 90 to 120 days ago, and your body is fully accepting the donor cells.
- You are generally well enough to do daily activities (score of 0–2 on the ECOG scale).
- Your liver, kidney, heart, and blood counts are within acceptable ranges.
- You do not have signs of the disease coming back or leftover abnormal cells before starting this treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether selinexor combined with azacitidine and venetoclax can treat newly diagnosed acute myeloid leukemia (AML) in people who may not be able to tolerate intensive chemotherapy. It’s aimed at improving leukemia control with a treatment approach designed for patients with higher risk from other health problems.
This trial tests different maintenance therapies based on the specific gene mutations in your leukemia or MDS after a stem cell transplant. Your doctor will choose the right drug for your mutation type to help keep the cancer from coming back.
This trial tests a combination of two drugs (SHR2554 and azacitidine) given before a stem cell transplant for people with high-risk or relapsed leukemia or MDS. The goal is to see if this approach can help make the transplant more effective and reduce the chance of the disease coming back.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This phase 2 study tests whether doctors can choose the best AML treatment plan using a special blood/marrow test done on day 14. It may help people who are not good candidates for intensive chemotherapy by adjusting therapy based on early response.
This trial tests whether giving two medicines, called selinexor and melphalan, twice a week after a stem cell transplant can help prevent acute myeloid leukemia from coming back. It's for people with high-risk AML who are 55 or older and whose cancer is in remission before the transplant.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.